{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:40:54Z","timestamp":1745469654657,"version":"3.40.4"},"reference-count":27,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2010]]},"abstract":"<i>Background:<\/i> This laboratory study was undertaken to investigate the influence of bevacizumab on apoptosis, Na<sup>+<\/sup>-K<sup>+<\/sup>-adenosine triphosphatase (Na<sup>+<\/sup>-K<sup>+<\/sup>-ATPase) and zonula occludens 1 (ZO-1) expression on cultured human corneal endothelial cells (HCECs). <i>Methods:<\/i> Annexin V binding combined with propidium iodide (PI) costaining was used to distinguish viable, early and late apoptotic cells. Immunolocalization of ZO-1 and Na<sup>+<\/sup>-K<sup>+<\/sup>-ATPase was performed to analyze intercellular cell integrity after exposure to 5.0 mg\/ml bevacizumab for 24 h. <i>Results:<\/i> No significant induction of apoptosis or necrosis was seen in HCECs after exposure to 5.0 mg\/ml bevacizumab (p = 0.689, p = 0.516, respectively). The mean number of annexin-V-FITC- and PI-positive cells did not change significantly. Additionally, no significant changes in expression were detectable, neither for ZO-1 nor for Na<sup>+<\/sup>-K<sup>+<\/sup>-ATPase in comparison with the control. For ZO-1, 70.0% of the cells stained intensely, 24.7% stained moderately, and 5.3% stained weakly in the control group. After exposure to 5.0 mg bevacizumab, only minor changes were observable: 68.8% stained intensely, 25.4% moderately and 5.8% weakly (p = 0.524). For Na<sup>+<\/sup>-K<sup>+<\/sup>-ATPase, 19.3% of the cells stained intensely, 59.4% moderately, and 21.3% weakly in the control group. After exposure to 5.0 mg bevacizumab, again only minor changes were observable in the expression pattern: 18.2% stained intensely, 60.3% moderately and 21.5% weakly. The changes were not significant compared with the control (p = 0.492). <i>Conclusions:<\/i> Bevacizumab, at concentrations used clinically, did not induce apoptosis or necrosis in HCECs in vitro. Additionally, no alteration of ZO-1 or Na<sup>+<\/sup>\/K<sup>+<\/sup>-ATPase expression was detected after exposure to 5.0 mg\/ml bevacizumab for 24 h.<\/jats:p>","DOI":"10.1159\/000286339","type":"journal-article","created":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T07:45:10Z","timestamp":1266565510000},"page":"43-49","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Bevacizumab on Apoptosis, Na<sup>+<\/sup>-K<sup>+<\/sup>-Adenosine Triphosphatase and Zonula Occludens 1 Expression on Cultured Corneal Endothelial Cells"],"prefix":"10.1159","volume":"44","author":[{"given":"Efdal","family":"Yoeruek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olcay","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oguzhan","family":"Saygili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl U.","family":"Bartz-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Szurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2010,2,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199412013312203"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00417-007-0684-4"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00417-007-0587-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097%2F00003226-200007000-00025"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.2479986"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa042760"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001%2Farchopht.124.11.1532"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa054481"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ophtha.2005.11.019"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097%2F00006982-200603000-00005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ajo.2006.06.066"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ajo.2006.02.045"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136%2Fbjo.2007.133496"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2FS1350-9462%2802%2900065-4"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1167%2Fiovs.07-1079"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1167%2Fiovs.04-0439"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jcrs.2008.08.024"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e3180de1d0a"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10555-007-9071-1"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016%2F0022-1759%2895%2900072-I"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097%2FIJG.0b013e3180457c47"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097%2F00006982-200603000-00017"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e31818b8be0"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e318180e572"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ajo.2008.06.002"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.exer.2004.09.012"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.preteyeres.2007.02.001"}],"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/286339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/286339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:35:08Z","timestamp":1745440508000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000286339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000286339","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"type":"print","value":"0030-3747"},{"type":"electronic","value":"1423-0259"}],"subject":[],"published":{"date-parts":[[2010]]}}}